Home / Intelligence / Webinars / Dragon’s Offer: Imparting Wisdom About Market Access Through the NRDL in China
Available On Demand
What do pharmaceutical manufacturers need to know to successfully navigate the market access landscape in China through the latest NRDL update?
The access landscape in China is rapidly evolving with important implications for novel medicines. The most recent update of China’s National Reimbursement Drug List (NRDL) in 2021 focused on the expansion of new and high-cost innovative therapies and highlighted the improving access environment for these drugs.
In this webinar, Trinity Life Sciences’ Value, Access and Pricing experts will provide an overview of the market access landscape in China with an in-depth analysis of the 2021 NRDL. We will discuss the pricing implications needed to secure public funding in China, along with how to navigate key NRDL strategies.
The dragon is an important symbol in East Asian culture, representing wisdom and power. Join our experts as they impart knowledge to empower your market access strategies.
Trinity continues to explore this topic. Click on the links to read our past blog posts about market access opportunities for rare disease and oncology products in China based on the 2020 NRDL.
Key topics
- Introduction to the NRDL and overview of the access landscape in China
- Key features of the 2021 NRDL update
- In-depth analysis of oncology and rare disease drug reimbursement
Complete the form below to view the on-demand webinar.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
White Papers
2023 NRDL Pricing Implementation and Market Access Outcomes Update
The National Reimbursement Drug List (NRDL) negotiations are expected to conclude by November 2024, with pricing outcomes gradually being revealed starting in January 2025. The Trinity Life Sciences team has reviewed the 2023 NRDL inclusion and pricing results, drawing some key learnings.
Read More
Blog
Early China Launch of PIASKY® in the Fight Against PNH
In February 2024, the National Medical Products Administration (NMPA), China’s drug regulator, granted priority review approval to Roche’s PIASKY (crovalimab), an injectable C5 inhibitor for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). PNH is a rare genetic blood disorder in which the patient’s immune system attacks and destroys red blood cells and platelets. As the […]
Read More
Blog
Rise with the Waves: UK – Now and Beyond – Four Policy Trends That May Shape Pharma’s Future
Executive Summary The global payer landscape is rapidly evolving and is expected to continuously impact manufacturers’ decisions about new launches, portfolio management, trial design and importantly, pricing and market access strategy. In the UK, several policy reforms have been introduced which are expected to improve patient access while balancing financial healthcare sustainability and overall market […]
Read More